

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/377655906>

B Cell Dysfunction in HIV: Implications for Novel Therapeutic Strategies

Article in *Haematology International Journal* · January 2024

DOI: 10.23880/hij-16000225

CITATIONS

0

1 author:



[Emmanuel Ifeanyi Obeagu](#)

Kampala International University (KIU)

1,290 PUBLICATIONS 7,594 CITATIONS

[SEE PROFILE](#)



B Cell Dysfunction in HIV: Implications for Novel Therapeutic Strategies

Emmanuel Ifeanyi Obeagu*

Department of Medical Laboratory Science, Kampala International University, Uganda

***Corresponding author:** Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Kampala, Uganda, Tel: +2348037369912; Email: emmanuelobeagu@yahoo.com; obeagu.emmanuel@kiu.ac.ug

Review Article

Volume 8 Issue 1

Received Date: January 3, 2024

Published Date: January 24, 2024

DOI: 10.23880/hij-16000225

Abstract

Human Immunodeficiency Virus (HIV) infection remains a global health challenge, characterized by progressive immune dysregulation leading to acquired immunodeficiency syndrome (AIDS). Among the myriad immune alterations observed in HIV, dysfunction of B lymphocytes plays a significant role in disease progression. This review article critically examines the multifaceted dysregulation of B cells during HIV infection, encompassing altered phenotypes, impaired functions, and disrupted interactions within the immune microenvironment. The dysregulation of B cells in HIV involves diverse mechanisms, including direct viral effects, chronic immune activation, and alterations in the cytokine milieu. Such dysfunction manifests as compromised antibody production, perturbed B cell subsets, impaired memory responses, and aberrant cytokine secretion, contributing to diminished humoral immunity and immune dysregulation. Understanding these intricacies is pivotal for elucidating the pathogenesis of HIV and developing targeted therapeutic strategies. This paper delineates the implications of B cell dysfunction for HIV-associated therapies. It highlights promising approaches, including immunotherapies targeting B cell function modulation, potential modifications or adjunctive therapies alongside standard antiretroviral therapy (ART) to address B cell abnormalities, and innovative strategies aimed at restoring humoral immunity in HIV-infected individuals. The elucidation of B cell dysregulation in HIV pathogenesis offers a unique avenue for therapeutic interventions. Targeting B cell dysfunction not only aims to restore humoral immunity but also holds promise in ameliorating overall immune function, potentially augmenting current HIV treatment paradigms.

Keywords: B-cell Dysfunction; HIV; Therapeutic Strategies; Immunotherapy; Antiretroviral Therapy; Humoral Immunity

Abbreviations: HIV: Human Immunodeficiency Virus; AIDS: acquired immunodeficiency syndrome; ART: Antiretroviral Therapy; bNAb: broadly Neutralizing Antibodies

Introduction

Human Immunodeficiency Virus (HIV) infection remains a global health crisis, with approximately 38

million people worldwide living with the virus. Despite significant advancements in antiretroviral therapy (ART) that have substantially improved the management of HIV, achieving a functional cure or complete eradication remains elusive. A hallmark of HIV infection is the progressive and complex dysregulation of the immune system, leading to acquired immunodeficiency syndrome (AIDS) [1-10]. Among the various immune perturbations observed during HIV infection, B lymphocytes, crucial mediators of humoral

immunity, undergo multifaceted alterations that significantly impact disease progression [11]. B cells play a pivotal role in the immune response, orchestrating antibody production, antigen presentation, and modulation of immune responses through cytokine secretion and interactions with other immune cells [12]. However, in the context of HIV infection, B cell dysfunction disrupts these critical functions, contributing to compromised humoral immunity and immune dysregulation [13-15].

Understanding the intricacies of B cell dysfunction in HIV pathogenesis is essential for comprehensively unraveling the disease mechanisms and identifying potential therapeutic targets. This paper aims to provide a comprehensive analysis of the multifaceted dysregulation of B cells during HIV infection, elucidating the implications of these alterations for the development of innovative therapeutic strategies. Addressing the complexities of B cell dysfunction in HIV pathogenesis and its far-reaching implications for therapeutic interventions holds significant promise in advancing the current understanding of HIV immunopathology and fostering the development of targeted strategies to mitigate immune dysregulation [16-21].

B Cell Dysfunction in HIV Pathogenesis

Human Immunodeficiency Virus (HIV) infection is characterized by a myriad of immune dysregulations, among which alterations in B lymphocytes significantly contribute to disease progression. The intricate interplay between HIV and B cells results in multifaceted dysfunction, impacting various aspects of humoral immunity and immune regulation [22-27]. HIV infection leads to alterations in B cell phenotypes, including changes in surface markers, activation status, and maturation profiles. Heightened activation and

exhaustion markers coupled with diminished naïve B cell populations and expansions of exhausted or atypical memory B cells characterize the phenotypic changes observed in HIV-infected individuals. This aberrant B cell phenotype is indicative of chronic immune activation and perturbed B cell homeostasis, contributing to functional deficiencies [28-34]. A hallmark of HIV-related B cell dysfunction is the impairment in antibody production. Despite increased B cell activation, hypergammaglobulinemia, and elevated antibody titers, these antibodies often display reduced specificity, decreased affinity, and impaired functionality against HIV antigens. Dysregulated germinal center reactions and impaired class-switching contribute to the suboptimal production of effective antibodies, thereby compromising the ability to neutralize the virus efficiently [35].

HIV-mediated dysregulation affects various B cell subsets, including memory B cells crucial for mounting effective immune responses. Depletion of specific memory B cell subsets, particularly those responsible for long-term immune memory, compromises the ability to generate robust and sustained responses upon re-exposure to antigens. Additionally, dysfunctional germinal center reactions impair the generation of high-affinity antibodies and long-lived plasma cells, further impeding effective humoral immunity against HIV [35-40]. The cytokine milieu within the B cell microenvironment undergoes significant alterations during HIV infection. Dysregulated production of cytokines, such as IL-6, IL-10, and TNF- α , contributes to B cell hyperactivation, immune exhaustion, and impaired differentiation. Chronic immune activation and persistent inflammation create an environment that disrupts normal B cell function, perpetuating immune dysregulation and compromising overall immune homeostasis [41-46].

Stage	Key Elements	Interactions and Consequences
1. Initial Infection	HIV - CD4+ T Cells	Binding of gp120 to CD4 receptors on T cells
2. Immune Activation	Immune Activation	Chronic activation triggered by HIV
3. Inflammation	Inflammation	Increased levels of pro-inflammatory cytokines
4. Direct Effects on B Cells	Direct B Cell Infection	HIV infects B cells directly
	Tfh Depletion	Depletion of Tfh
5. Consequences on B Cell Functionality	Germinal Center Disruption	Impaired germinal center reactions
	Cytokine Dysregulation	Altered cytokine production
	Memory B Cell Dysfunction	Reduced memory B cell responses
6. Clinical Manifestations	Hypergammaglobulinemia	Paradoxical increase in total immunoglobulin levels
	Increased Susceptibility to Opportunistic Infections	Greater susceptibility to infections

Table 1: Pathogenetic Network of B-Cell Deficiency in HIV.

HIV exerts direct effects on B cells, impacting their functionality. Viral proteins and viral replication in B cells contribute to their dysfunction by promoting apoptosis, impairing signaling pathways, and altering B cell receptor-mediated responses. This direct viral interference exacerbates B cell dysfunction, adding to the complexity of HIV-induced immune dysregulation [47-52]. The multifaceted alterations in B cell phenotypes, impaired antibody production, perturbed subsets, and dysregulated microenvironment collectively contribute to compromised humoral immunity and immune dysregulation in HIV infection. Understanding these mechanisms of B cell dysfunction is pivotal for devising targeted therapeutic strategies to restore B cell functionality and mitigate HIV-associated immune impairment [53-57] (Table 1).

Implications for HIV-Associated Therapies

Understanding the multifaceted dysregulation of B cells in HIV infection opens avenues for innovative therapeutic interventions aimed at restoring immune function and augmenting current treatment strategies. Addressing B cell dysfunction holds promise for enhancing immune responses, reducing viral persistence, and improving overall treatment outcomes in HIV-infected individuals. Emerging immunotherapeutic approaches targeting B cell function modulation present a promising avenue for addressing B cell dysfunction in HIV. Strategies involving monoclonal antibodies targeting specific B cell markers or cytokines aim to modulate B cell activation, exhaustion, or aberrant immune responses. These therapies offer potential in restoring functional B cell subsets, optimizing antibody production, and enhancing humoral immunity against HIV [58-63].

Complementary therapies alongside standard antiretroviral therapy (ART) focus on mitigating B cell abnormalities to enhance treatment efficacy. Identifying adjunctive therapies that specifically target B cell dysfunction could aid in augmenting the immunological benefits of ART. This approach aims to preserve or restore B cell function, potentially reducing residual viral reservoirs and fostering a more robust immune response against HIV [64-69]. Strategies aimed at restoring humoral immunity in HIV-infected individuals constitute a critical aspect of therapeutic interventions. Vaccination approaches tailored to boost B cell responses, therapeutic vaccines designed to elicit potent and broadly neutralizing antibodies, and adjuvant therapies to enhance antibody production represent avenues for restoring effective humoral immunity against HIV [70-72]. Further research into innovative approaches targeting B cell-centric therapies is essential. This includes exploring adoptive B cell therapy, engineered B cells with enhanced antiviral properties, or approaches leveraging advancements in gene editing to modify B cells. Such pioneering strategies

hold promise in restoring functional B cell populations and fostering durable immune responses in HIV infection [73-78].

While these therapeutic avenues show promise, challenges such as potential adverse effects, identification of optimal targets, patient-specific variations, and long-term efficacy need careful consideration. Additionally, addressing B cell dysfunction necessitates a comprehensive understanding of the interplay between B cells and other immune components, emphasizing the need for multidisciplinary approaches and collaborative research endeavors. The implications of addressing B cell dysfunction in HIV-associated therapies are vast, offering avenues to augment current treatment paradigms and potentially move closer to achieving improved control or eradication of the virus. Developing targeted strategies aimed at restoring functional B cell subsets and enhancing humoral immunity represents a promising frontier in the quest for more effective HIV therapies.

Immunotherapy Approaches

Immunotherapeutic interventions targeting B cell dysfunction in HIV infection represent a promising frontier in HIV treatment strategies [78]. These approaches aim to modulate B cell function, restore immune homeostasis, and enhance humoral immunity against the virus. Several innovative immunotherapy strategies are currently under investigation for their potential in ameliorating B cell dysfunction in HIV-infected individuals. Monoclonal antibodies (mAbs) targeting specific B cell markers, such as CD20 or CD19, hold potential for selectively depleting aberrant B cell subsets or modulating B cell activation and function [79]. Strategies involving mAbs directed against cytokines implicated in B cell dysregulation (e.g., IL-6, IL-10) aim to alleviate B cell exhaustion and restore functional B cell subsets, thereby enhancing humoral immunity against HIV. Development of B cell-targeted immunomodulators focuses on agents capable of modulating B cell signaling pathways or activation states. Small molecule inhibitors or biologics targeting signaling molecules involved in B cell activation, survival, or differentiation pathways offer potential in restoring normal B cell function and reversing the state of B cell exhaustion observed in HIV infection [80].

Adoptive B cell therapy involves the *ex vivo* expansion and modification of autologous B cells before reinfusion into patients. This approach could be utilized to enrich for functional B cell subsets, enhance antibody production, or engineer B cells to express broadly neutralizing antibodies or other antiviral molecules. Adoptive transfer of engineered or augmented B cells aims to bolster the host's immune response against HIV [81]. Bispecific antibodies designed

to target both B cells and specific viral epitopes represent an innovative strategy. These engineered antibodies aim to redirect B cell-mediated immune responses towards effective viral neutralization or elimination. Bispecific antibodies offer the potential to enhance the specificity and efficacy of B cell-mediated antiviral responses in HIV-infected individuals [82]. While these immunotherapy approaches hold promise, challenges such as potential side effects, optimal dosing strategies, long-term safety, and efficacy in diverse patient populations need careful consideration. Moreover, personalized approaches considering individual variations in B cell responses and viral strain differences are essential for the successful implementation of these strategies. Immunotherapy strategies targeting B cell dysfunction in HIV infection offer exciting possibilities for enhancing immune function and potentially altering the course of the disease. Continued research and clinical trials exploring these innovative approaches are crucial for validating their efficacy, safety, and potential role in future HIV treatment paradigms.

Antiretroviral Therapy and B Cell Function

Antiretroviral therapy (ART) has revolutionized the management of HIV infection, effectively suppressing viral replication, reducing morbidity and mortality, and restoring immune function. However, while ART significantly improves overall immune health, its impact on specific aspects of B cell function in HIV-infected individuals is multifaceted and complex. ART initiation leads to a reduction in systemic immune activation, which subsequently impacts B cell activation levels. Studies suggest that ART-mediated viral suppression decreases generalized B cell activation, resulting in partial restoration of some B cell subsets, such as memory B cells and naïve B cells. However, complete normalization of B cell phenotypes and functional subsets might not occur, as certain B cell alterations persist despite virological suppression [83,84].

ART-mediated viral suppression can positively impact the quality and specificity of antibodies produced by B cells. Enhanced antibody responses against HIV antigens and a shift towards more functional antibodies with increased affinity and specificity have been observed following ART initiation. However, some individuals may still exhibit impaired antibody responses or reduced efficacy against specific viral strains due to persistent B cell dysfunction [85]. The extent of B cell recovery and its implications for immune reconstitution in HIV-infected individuals on ART vary among patients. While some individuals demonstrate substantial restoration of B cell subsets and functionality, others exhibit persistent B cell abnormalities despite long-term viral suppression. Factors such as the timing of ART

initiation, pre-existing immune damage, and residual viral reservoirs may influence the degree of B cell recovery. Despite its benefits in suppressing viral replication and reducing immune activation, ART alone might not fully restore normal B cell function. Persistent immune activation, residual viral reservoirs, ongoing inflammation, and chronic immune dysregulation contribute to sustained B cell dysfunction in some individuals, necessitating adjunctive therapies to specifically target B cell abnormalities. Recognizing the incomplete restoration of B cell function by ART alone, research efforts focus on identifying complementary therapies or adjunctive interventions that specifically address B cell dysfunction. Combined therapeutic strategies, such as immunomodulatory agents or targeted immunotherapies, aim to optimize B cell function alongside ART to achieve more comprehensive immune reconstitution. Antiretroviral therapy plays a pivotal role in controlling HIV replication and mitigating immune activation. While ART contributes to partial restoration of B cell subsets and functional improvements in antibody responses, persistent B cell dysfunction remains a challenge. Addressing these limitations through adjunctive therapies targeting B cell abnormalities holds promise for achieving more comprehensive immune recovery in HIV-infected individuals [86].

Restoring Humoral Immunity

Restoring humoral immunity, primarily mediated by B cells and antibodies, represents a critical aspect of therapeutic interventions in HIV infection. Strategies targeting the enhancement of B cell function and the production of effective antibodies aim to bolster immune responses against the virus and mitigate the impact of HIV-induced immune dysregulation [87]. Tailored vaccination approaches designed to augment B cell responses and induce robust antibody production are being explored in HIV-infected individuals. Vaccine candidates, including HIV-specific vaccines or adjuvanted formulations, aim to stimulate potent and durable humoral immune responses. Strategies that promote germinal center reactions and facilitate the generation of broadly neutralizing antibodies (bNAbs) are actively investigated to elicit more effective antiviral immunity. Therapeutic vaccines, administered to individuals already infected with HIV, seek to boost immune responses against the virus. These vaccines aim to enhance B cell-mediated immunity, stimulate cytotoxic T cell responses, and potentially reduce viral reservoirs. The focus is on eliciting robust humoral responses, including the production of neutralizing antibodies, to control viral replication and prevent disease progression.

Adjuvant therapies aimed at potentiating antibody production constitute another approach to restoring humoral

immunity in HIV-infected individuals. Strategies involving cytokine adjuvants, such as IL-7 or IL-21, or immune checkpoint inhibitors aim to enhance B cell activation, proliferation, and differentiation, thereby improving the quality and functionality of antibodies generated in response to HIV antigens [88]. Efforts to develop vaccines specifically targeting the induction of broadly neutralizing antibodies (bNAbs) against conserved regions of the HIV envelope glycoprotein are underway. These vaccines aim to overcome the high variability of the virus and induce potent and broadly effective antibodies capable of neutralizing diverse HIV strains. Strategies include mimicking viral epitopes to prompt the production of bNAbs or utilizing novel vaccine platforms to elicit these protective antibodies. Recognizing the multifaceted nature of HIV-induced immune dysregulation, combination approaches integrating vaccination strategies, therapeutic vaccines, adjuvant therapies, and innovative antibody-inducing regimens are being investigated. Complementary interventions targeting different facets of humoral immunity aim to synergistically enhance B cell function, optimize antibody responses, and potentially confer durable protection against HIV. Restoring humoral immunity in HIV-infected individuals through targeted vaccination strategies, therapeutic vaccines, adjuvant therapies, and approaches aimed at inducing broadly neutralizing antibodies holds significant promise. These innovative approaches seek to bolster B cell-mediated immune responses, mitigate viral replication, and potentially alter the trajectory of HIV infection by enhancing the host's ability to mount effective humoral immunity.

Challenges and Future Directions

Despite advancements in understanding B cell dysfunction in HIV infection and the development of therapeutic interventions, several challenges persist, hindering the comprehensive management of immune dysregulation. Exploring future directions and addressing these challenges is crucial for optimizing therapeutic strategies targeting B cell abnormalities in HIV. The heterogeneity of B cell responses among HIV-infected individuals poses a significant challenge. Variations in B cell phenotypes, functionality, and responses to therapy exist among patients, necessitating personalized approaches tailored to individual immune profiles. Characterizing and understanding this heterogeneity is crucial for devising targeted and effective therapeutic interventions. Persistent B cell dysfunction observed in some individuals despite virological suppression by antiretroviral therapy (ART) underscores the incomplete restoration of normal immune function. Identifying the mechanisms contributing to sustained B cell abnormalities and elucidating the interplay between viral reservoirs, chronic inflammation, and immune dysregulation are essential to address these limitations.

Determining the optimal timing for initiating targeted therapies to address B cell dysfunction remains a challenge. Deciphering the ideal stage of HIV infection or disease progression for implementing adjunctive B cell-targeted interventions alongside standard ART is crucial. Furthermore, exploring the potential of combination therapies integrating multiple approaches to optimize B cell function is warranted. Assessing the long-term efficacy and safety of novel interventions targeting B cell dysfunction in HIV is essential. Clinical trials evaluating the durability of immune responses, potential adverse effects, and sustained benefits of therapeutic strategies are necessary to validate their utility and establish their role in routine clinical practice. The intricate interplay between B cell dysfunction, viral persistence, chronic inflammation, and immune exhaustion in HIV infection presents a complex challenge. Understanding the multifaceted mechanisms contributing to immune dysregulation and the dynamic interactions between viral and host factors is crucial for developing more effective and targeted therapeutic interventions.

Future directions in therapeutic innovation involve continued research into advanced immunotherapies, novel vaccine platforms, engineered antibody-based approaches, and gene-editing technologies targeting B cell abnormalities. Additionally, exploring immune modulation strategies and leveraging emerging technologies to tailor personalized therapies represent promising avenues. Addressing the challenges in B cell-targeted therapies for HIV requires a concerted effort toward further research, collaboration among multidisciplinary teams, and ongoing clinical trials. Advancing therapeutic strategies necessitates a comprehensive understanding of the complex immunopathogenesis of HIV, paving the way for innovative interventions and personalized approaches tailored to enhance B cell function and restore immune homeostasis.

Recommendations

Tailoring therapeutic interventions based on individual variations in B cell responses and disease progression is critical. Developing personalized treatment regimens accounting for diverse B cell profiles could optimize therapeutic efficacy. Exploring combination therapies integrating multiple strategies targeting B cell dysfunction alongside standard ART could enhance immune reconstitution. Combining immunotherapies, adjuvant therapies, and vaccination strategies may offer synergistic benefits. Conducting longitudinal studies and robust clinical trials is imperative for evaluating the long-term efficacy, safety, and durability of interventions targeting B cell abnormalities. Continuous assessment and follow-up are crucial to validate the utility of therapeutic strategies.

Investigating early intervention strategies aimed at preserving B cell function before extensive immune damage occurs could potentially mitigate long-term immune dysregulation. Identifying optimal timings for initiating targeted therapies is essential for maximal efficacy. Fostering collaboration between basic science researchers, clinicians, immunologists, and virologists is essential for translational research efforts. Collaborative initiatives can bridge gaps between laboratory discoveries and clinical applications. Emphasizing research on strategies that promote comprehensive immune reconstitution, including restoring functional B cell subsets and enhancing humoral immunity, could redefine treatment approaches for HIV-infected individuals.

Establishing systems for continuous monitoring of immune responses and viral dynamics in HIV-infected individuals undergoing B cell-targeted therapies is vital. Adapting interventions based on patient responses and emerging scientific findings is crucial for refining treatment protocols. Promoting education and public awareness regarding the role of B cells in HIV pathogenesis and the potential of innovative therapeutic strategies can empower both healthcare providers and individuals living with HIV. Encouraging sustained investment in research funding and technological advancements is essential to drive innovation in B cell-focused therapies. Novel technologies, such as gene editing and advanced immunotherapies, hold promise and warrant continued exploration. Ensuring equitable access to emerging therapies, considering ethical implications, and addressing disparities in healthcare access are critical aspects of implementing novel interventions targeting B cell dysfunction in HIV on a global scale. Implementing these recommendations could advance the development and implementation of targeted therapeutic strategies aimed at restoring B cell function and enhancing immune responses in HIV-infected individuals, ultimately contributing to improved clinical outcomes and quality of life.

Conclusion

Understanding the intricate interplay between B cell dysfunction and HIV infection is crucial for devising effective therapeutic strategies aimed at restoring immune function and mitigating the impact of immune dysregulation. B lymphocytes, pivotal in humoral immunity, undergo multifaceted alterations during HIV pathogenesis, impacting antibody production, subset distribution, and immune homeostasis. Advancements in antiretroviral therapy (ART) have significantly improved viral suppression and overall immune health in HIV-infected individuals. However, persistent B cell dysfunction persists in some cases, indicating the incomplete restoration of normal immune function solely through ART. Exploring innovative approaches, including

immunotherapy, vaccination strategies, adjuvant therapies, and targeted interventions, offers promising avenues for restoring humoral immunity and optimizing B cell function. These strategies aim to enhance antibody responses, induce broadly neutralizing antibodies, modulate B cell activation, and mitigate chronic immune activation to achieve more comprehensive immune reconstitution.

Moving forward, investment in research, fostering collaborations, emphasizing early interventions, continuous monitoring, and addressing ethical considerations are pivotal for translating scientific advancements into clinical applications. Empowering healthcare providers, individuals living with HIV, and the public through education and awareness remains essential in implementing and optimizing these innovative therapeutic approaches. Efforts aimed at restoring B cell function and enhancing humoral immunity hold promise in reshaping the landscape of HIV treatment, potentially leading to improved clinical outcomes, reduced disease progression, and enhanced quality of life for those affected by HIV infection. Continued dedication to research, innovation, and multidisciplinary collaboration is essential in the ongoing pursuit of more effective therapies against HIV-induced immune dysregulation.

References

1. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU (2022) Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences* 2(3): 120-127.
2. Obeagu EI, Alum EU, Obeagu GU (2023) Factors associated with prevalence of HIV among youths: A review of Africa perspective. *Madonna University journal of Medicine and Health Sciences* 3(1): 13-18.
3. Obeagu EI (2023) A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences* 3(1): 7-12.
4. Obeagu EI, Obeagu GU (2023) An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri* 6(2): 141:1-2.
5. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, et al. (2021) Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International* 33(4): 10-19.
6. Omo Emmanuel UK, Chinedum OK, Obeagu EI (2017)

- Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci* 3(1): 21-38.
7. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO (2023) Factors contributing to low utilization of HIV counseling and testing services. *Int J Curr Res Med Sci* 9(2): 1-5.
 8. Obeagu EI, Obeagu GU (2022) An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri* 5(6) 129.
 9. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, et al. (2021) Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International* 33: 10-19.
 10. Sokoya T, Steel HC, Nieuwoudt M, Rossouw TM (2017) HIV as a cause of immune activation and immunosenescence. Mediators of inflammation.
 11. Leon B, Ballesteros-Tato A, S Misra R, Wojciechowski W, E Lund F (2012) Unraveling effector functions of B cells during infection the hidden world beyond antibody production. *Infect Disord Drug Targets* 12(3): 213-21.
 12. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, et al.(2020) TB Infection Control in TB/HIV Settings in Cross River State Nigeria Policy Vs Practice. *Journal of Pharmaceutical Research International* 32(22): 101-109.
 13. Obeagu EI, Eze VU, Alaebob EA, Ochei KC (2016) Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation* 5: 464-471.
 14. Ifeanyi OE, Obeagu GU (2015) The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences* 4(4): 911-6.
 15. Fakharian F, Thirugnanam S, Welsh DA, Kim WK, Rappaport J, et al. (2023) The role of gut dysbiosis in the loss of intestinal immune cell functions and viral pathogenesis. *Microorganisms* 11(7): 1849.
 16. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, et al. (2016) Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int J Adv Res Biol Sci* 3(10): 55-65.
 17. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, et al. (2017) HIV and TB co-infection among patients who used Directly Observed Treatment Short course centres in Yenagoa Nigeria. *IOSR J Pharm Biol Sci* 12(4): 70-5.
 18. Oloro OH, Oke TO, Obeagu EI (2022) Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences* 2(3):110-119.
 19. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, et al. (2016) Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State. *J Bio Innov* 5(1): 24-30.
 20. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, et al. (2016) Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State Nigeria. *J Bio Innov* 5(1): 24-30.
 21. Igwe CM, Obeagu IE, Ogbuabor OA (2022) Clinical Characteristics of People Living with HIV/AIDS on ART in 2014 at Tertiary Health Institutions in Enugu. *J Pub Health Nutri* 5(6): 130.
 22. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI (2015) The Values of Activated Partial Thromboplastin Time (APTT) among HIV Positive Patients in FMC Owerri. *Int J Curr Res Aca Rev* 3(4): 139-144.
 23. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO (2018) Haematological Indices of HIV Seropositive Subjects at Nnamdi Azikiwe University Teaching Hospital (Nauth), Nnewi. *Ann Clin Lab Res* 6(1): 221.
 24. Omo Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF (2017) Impact of Prevention of Mother to Child Transmission (PMTCT) of HIV on Positivity Rate in Kafanchan, Nigeria. *Int J Curr Res Med Sci* 3(2): 28-34.
 25. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI (2022) Alarming Rise in HIV Cases in Pakistan: Challenges and Future Recommendations at Hand. *Health Sci Rep* 6(8): e1450.
 26. Obeagu EI, Amekpor F, Scott GY, Okwuanaso BC (2023) An Update of Human Immunodeficiency Virus Infection: Bleeding Disorders. *J Pub Health Nutri* 6(1): 139.
 27. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, et al. (2022) Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University*

- Journal of Medicine and Health Sciences 2(3): 128-134.
28. Moir S, Fauci AS (2017) B-cell Responses to HIV Infection. *Immunol Rev* 275(1): 33-48.
 29. Moir S, Fauci AS (2013) Insights into B Cells and HIV-specific B-cell Responses in HIV-infected Individuals. *Immunol Rev* 254(1): 207-224.
 30. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL (2022) Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International* 34(3A): 29-34.
 31. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, et al. (2020) Cascade Variabilities in TB Case Finding among People Living with HIV and the Use of IPT: Assessment in Three Levels of Care in Cross River State, Nigeria. *Journal of Pharmaceutical Research International* 32(24): 9-18.
 32. Jakheng SP, Obeagu EI (2022) Seroprevalence of Human Immunodeficiency Virus Based on Demographic and Risk Factors Among Pregnant Women Attending Clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri* 5(6): 127.
 33. Obeagu EI, Obeagu GU (2023) A Review of Knowledge, Attitudes and Socio-demographic Factors Associated with Non-adherence to Antiretroviral Therapy among People Living with HIV/AIDS. *Int J Adv Res Biol Sci* 10(9): 135-142.
 34. Obeagu EI, Onuoha EC (2023) Tuberculosis among HIV Patients: A Review of Prevalence and Associated Factors. *Int J Adv Res Biol Sci* 10(9): 128-134.
 35. Amu S, Ruffin N, Rethi B, Chiodi F (2013) Impairment of B-cell Functions During HIV-1 Infection. *AIDS* 27(15): 2323-2334.
 36. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP (2017) Haematological Indices of Malaria Patients Coinfected with HIV in Umuahia. *Int J Curr Res Med Sci* 3(5): 100-104.
 37. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, et al. (2022) Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology* 13(2):26-31.
 38. Viola N, Kimono E, Nuruh N, Obeagu EI (2023) Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. *Asian Journal of Dental and Health Sciences* 3(2): 7-14.
 39. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N (2020) Comparative Study of Enzyme linked Immunosorbent Assay (Elisa) and Rapid Test Screening Methods on HIV, Hbsag, Hcv and Syphilis among Voluntary Donors in Owerri, Nigeria. *J Clin & Commun Med* 2(3): 180-183.
 40. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, et al. (2021) Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International* 33(47A): 78-84.
 41. Liapis K, Clear A, Owen A, Coutinho R, Greaves P, et al. (2013) The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies. *Blood* 122(3): 424-433.
 42. Paiardini M, Muller Trutwin M (2013) HIV-associated Chronic Immune Activation. *Immunol Rev* 254(1): 78-101.
 43. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K (2023) Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth* 6(1): 203-211.
 44. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, et al. (2022) Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. *Asian Journal of Research in Infectious Diseases* 10(4): 1-7.
 45. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi Chigbu AC (2021) Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International* 33(57A): 360-368.
 46. Igwe MC, Obeagu EI, Ogbuabor AO (2022) Analysis of the Factors and Predictors of Adherence to Healthcare of People Living with Hiv/Aids in Tertiary Health Institutions in Enugu State. *Madonna University journal of Medicine and Health Sciences* 2(3): 42-57.
 47. Madekwe CC, Madekwe CC, Obeagu EI (2022) Inequality of Monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences* 2(3): 6-15.
 48. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, et al. (2023) Weights of Infants Born to HIV Infected

- Mothers: A Prospective Cohort Study in Federal Medical Centre, Owerri, Imo State. *European Journal of Pharmaceutical and Medical Research* 10(8): 564-568.
49. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, et al. (2015) Biochemical Alterations in Adult HIV Patients on Antiretroviral Therapy. *World Journal of Pharmacy and Pharmaceutical Sciences* 4(3): 153-160.
 50. Obeagu EI, Obeagu GU (2015) Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int J Curr Res Biosci Plant Biol* 2(4): 45-49.
 51. Obeagu EI, Nwosu DC (2019) Adverse Drug Reactions in HIV/AIDS Patients on Highly Active Antiretro Viral Therapy: A Review of Prevalence. *Int J Curr Res Chem Pharm Sci* 6(12): 45-48.
 52. Obeagu EI, Scott GY, Amekpor F, Obeagu GU (2023) Implications of CD4/CD8 Ratios in Human Immunodeficiency Virus Infections. *Int J Curr Res Med Sci* 9(2): 6-13.
 53. Obeagu EI, Ochei KC, Okeke EI, Anode AC (2016) Assessment of the Level of Hemoglobin and Erythropoietin in Persons Living with HIV in Umuahia. *Int J Curr Res Med Sci* 2(4): 29-33.
 54. Ifeanyi OE, Obeagu GU (2015) The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int J Curr Microbiol App Sci* 4(4): 906-910.
 55. Obeagu EI, Okeke EI, Anonde Andrew C (2016) Evaluation of Hemoglobin and Iron Profile Study among Persons Living with HIV in Umuahia, Abia State, Nigeria. *Int J Curr Res Biol Med* 1(2): 1-5.
 56. Alum EU, Ugwu OP, Obeagu EI, Okon MB (2023) Curtailing HIV/AIDS Spread: Impact of Religious Leaders. *Newport International Journal of Research in Medical Sciences (NIJRMS)* 3(2): 28-31.
 57. Obeagu EI, Obeagu GU, Paul Chima UO (2023) Stigma Associated With HIV. *AIDS: A Review. Newport International Journal of Public Health and Pharmacy (Nijpp)* 3(2): 64-67.
 58. Gupta SL, Khan N, Basu S, Soni V (2022) B-cell-based immunotherapy: A Promising New Alternative. *Vaccines* 10(6): 879.
 59. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB (2023) HIV Infection and Cardiovascular Diseases: The Obnoxious Duos. *Newport International Journal of Research in Medical Sciences (NIJRMS)* 3(2): 95-99.
 60. Ibebuikwe JE, Nwokike GI, Nwosu DC, Obeagu EI (2018) A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research* 1(2): 8-14.
 61. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB (2014) Assessment of Some Haematological and Biochemical Parameters in HIV Patients Before Receiving Treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci* 5(2): 825-830.
 62. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC (2014) Pattern of Total White Blood Cell and Differential Count Values in HIV Positive Patients Receiving Treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *Int J LifeSc Bt & Pharm Res* 3(1): 186-189.
 63. Obeagu EI (2023) A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences* 3(1): 7-12.
 64. Bloch M, John M, Smith D, Rasmussen TA, Wright E (2020) Managing HIV-associated Inflammation and Ageing in the Era of Modern ART. *HIV medicine* 21(3): 2-16.
 65. Oloro OH, Obeagu EI (2022) A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research* 10(5): 1-11.
 66. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanjo CA, Nwanjo HU, et al. (2015) Alterations in Superoxide Dismutase, Vitamins C and E in HIV Infected Children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences* 2(11): 268-271.
 67. Obeagu EI, Malot S, Obeagu GU, Ugwu OP (2023) HIV resistance in patients with Sick Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)* 3(2): 56-59.
 68. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC (2018) Vitamin D and Insulin Resistance in HIV Sero Positive Individuals in Umudike. *Int J Curr Res Med Sci* 4(2): 104-108.
 69. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK (2018) A Review on Blood Borne Viral Infections: Universal Precautions. *Int J Adv Res Biol Sci* 5(6): 60-66.
 70. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS (2018) Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory

Staff in Federal Teaching Hospital Abakaliki Ebonyi State. Arch Blood Transfus Disord 1(2).

HIV Infection: A Therapeutic Opportunity for HIV cure? Front Immunol 11: 1223.

71. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, et al. (2017) HIV and TB Co-infection among Patients Who Used Directly Observed Treatment Short-course Centres in Yenagoa, Nigeria. IOSR J Pharm Biol Sci 12(4): 70-75.
72. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, et al. (2021) Facilitators and Barriers to Retention in HIV Care Among HIV Infected MSM Attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International 33(52B): 10-19.
73. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA (2023) Translation of HIV/AIDS Knowledge into Behavior Change among Secondary School Adolescents in Uganda: A Review. Medicine (Baltimore) 102(49): e36599.
74. Anyiam AF, Arinze Anyiam OC, Ironi EA, Obeagu EI (2023) Distribution of ABO and Rhesus Blood Grouping with HIV Infection among Blood Donors in Ekiti State Nigeria. Medicine (Baltimore) 102(47): e36342.
75. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI (2023) Effect of Dolutegravir Regimen against other Regimens on Some Hematological Parameters, CD4 Count and Viral Load of People Living with HIV Infection in South Eastern Nigeria. Medicine (Baltimore) 102(47): e35910.
76. Opeyemi AA, Obeagu EI (2023) Regulations of Malaria in Children with Human Immunodeficiency Virus Infection: A Review. Medicine (Baltimore) 102(46): e36166.
77. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, et al. (2023) Inclusion of Nutritional Counseling and Mental Health Services in HIV/AIDS Management: A Paradigm Shift. Medicine (Baltimore) 102(41): e35673.
78. Chen H, Moussa M, Catalfamo M (2020) The Role of Immunomodulatory Receptors in the Pathogenesis of HIV Infection: A Therapeutic Opportunity for HIV cure? Front Immunol 11: 1223.
79. Lee DS, Rojas OL, Gommerman JL (2021) B Cell Depletion Therapies in Autoimmune Disease: Advances and Mechanistic Insights. Nat Rev Drug Discov 20(3): 179-199.
80. Davis JS, Ferreira D, Paige E, Gedye C, Boyle M (2020) Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clin Microbiol Rev 33(3): e00035-19.
81. Page A, Hubert J, Fusil F, Cosset FL (2021) Exploiting B Cell Transfer for Cancer Therapy: Engineered B Cells to Eradicate Tumors. Int J Mol Sci 22(18): 9991.
82. Fabozzi G, Pegu A, Koup RA, Petrovas C (2019) Bispecific Antibodies: Potential Immunotherapies for HIV Treatment. Methods 154: 118-124.
83. Regidor DL, Detels R, Breen EC, Widney DP, Jacobson LP, et al. (2011) Effect of Highly Active Antiretroviral Therapy on Biomarkers of B-Lymphocyte Activation and Inflammation. AIDS 25(3): 303-314.
84. Tanko RF, Soares AP, Muller TL, Garrett NJ, Samsunder N, et al. (2017) Effect of Antiretroviral Therapy on The Memory and Activation Profiles of B Cells in HIV-Infected African Women. J Immunol 198(3): 1220-1228.
85. Anderko RR, Mailliard RB (2023) Mapping the Interplay between NK Cells and HIV: Therapeutic Implications. J Leukoc Biol 113(2): 109-138.
86. Shi Y, Su J, Chen R, Wei W, Yuan Z, et al. (2022) The Role of Innate Immunity in Natural Elite Controllers of HIV-1 Infection. Front Immunol 13:780922.
87. Cooper L, Good Jacobson KL (2020) Dysregulation of Humoral Immunity in Chronic Infection. Immunol Cell Biol 98(6): 456-466.
88. Ward AR, Mota TM, Jones RB (2021) Immunological Approaches to HIV Cure. Semin Immunol 51: 101412.

